×

Cancer Genetics to Promote FHACT(TM) Test for Cervical Cancer at American Congress of Obstetricians and Gynecologists' Annual Clinical Meeting

RUTHERFORD, N.J., April 25, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, will be participating in the Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), being held April 26-30 at the McCormick Place Convention Center in Chicago, Illinois. ACOG is the premier gynecological conference in the U.S. The conference hosts more than 200 exhibitors, and features more than 400 original research posters and paper abstracts.

"This year's ACOG meeting is a great opportunity for us to communicate the value of our proprietary FHACT™ test for the management of cervical cancer to the clinical community and thought leaders in this Congress," said Jane Houldsworth, Vice President of Research and Development. "FHACT™ is a non-invasive genomic test that can identify lesions caused by persistent HPV infection and that are more likely to progress to a higher grade. By allowing for a better screening of patients before referral for colposcopy, the test can provide physicians with important information in making treatment decisions and potentially reduce costs and procedures that add to the U.S. healthcare costs."

This is the first year Cancer Genetics will have a commercial presence at ACOG. Company representatives will be located at Booth #939.

About FHACT™

FHACTTM (FISH-based HPV-Associated Cancer Test) is the only four color FISH(1) probe that can be used for cervical cancer screening as an additional test before referral for colposcopy. The test uses a unique combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q and chromosome 7. Research supporting the application of FHACT™ for the detection of chromosomal abnormalities observed in cervical cancers was published in the September 2013 issue of Gynecologic Oncology http://dx.doi.org/10.1016/j.ygyno.2013.06.005. FHACT™ can be used on the remnant liquid cytology (Pap smear) specimen (no resampling). The test is offered at CGI's CLIA laboratory in New Jersey.

(1) (fluorescence in situ hybridization)

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations RedChip Companies, Inc. Paul Kuntz, 800-733-2447, ext. 105 paul@redchip.comSource:Cancer Genetics

More From Press Releases